Evofem Biosciences (EVFM) Competitors $0.0088 0.00 (-10.20%) As of 03/31/2025 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock EVFM vs. IMCC, CNSP, TTNP, RDHL, MAAQ, NBY, PPBT, ATNF, SNPX, and INMShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include IM Cannabis (IMCC), CNS Pharmaceuticals (CNSP), Titan Pharmaceuticals (TTNP), RedHill Biopharma (RDHL), Mana Capital Acquisition (MAAQ), NovaBay Pharmaceuticals (NBY), Purple Biotech (PPBT), 180 Life Sciences (ATNF), Synaptogenix (SNPX), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. IM Cannabis CNS Pharmaceuticals Titan Pharmaceuticals RedHill Biopharma Mana Capital Acquisition NovaBay Pharmaceuticals Purple Biotech 180 Life Sciences Synaptogenix InMed Pharmaceuticals Evofem Biosciences (NASDAQ:EVFM) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Which has more volatility and risk, EVFM or IMCC? Evofem Biosciences has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Does the media prefer EVFM or IMCC? In the previous week, IM Cannabis had 4 more articles in the media than Evofem Biosciences. MarketBeat recorded 6 mentions for IM Cannabis and 2 mentions for Evofem Biosciences. IM Cannabis' average media sentiment score of 1.22 beat Evofem Biosciences' score of 0.28 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IM Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer EVFM or IMCC? Evofem Biosciences received 256 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformEvofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% IM CannabisOutperform Votes642.86% Underperform Votes857.14% Which has better valuation and earnings, EVFM or IMCC? Evofem Biosciences has higher earnings, but lower revenue than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$11.39M0.09$52.98M-$0.21-0.04IM Cannabis$51.39M0.07-$7.04M-$3.41-0.44 Is EVFM or IMCC more profitable? IM Cannabis has a net margin of -25.55% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% IM Cannabis -25.55%-129.86%-23.63% Do institutionals & insiders hold more shares of EVFM or IMCC? 0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryIM Cannabis beats Evofem Biosciences on 8 of the 15 factors compared between the two stocks. Remove Ads Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11M$6.90B$5.64B$7.79BDividend YieldN/A2.81%5.34%4.05%P/E Ratio-0.017.4223.6418.68Price / Sales0.09207.00371.1089.80Price / CashN/A65.6738.1734.64Price / Book0.006.206.734.12Net Income$52.98M$142.11M$3.20B$247.10M7 Day PerformanceN/A-7.28%-4.57%-3.13%1 Month PerformanceN/A-10.45%-0.21%-6.21%1 Year PerformanceN/A-12.86%7.93%-1.58% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.4936 of 5 stars$0.01-10.2%N/A-63.5%$1.11M$11.39M-0.01120Gap DownIMCCIM Cannabis1.4336 of 5 stars$1.79flatN/A-52.5%$4.00M$51.39M-0.53340Short Interest ↓News CoverageCNSPCNS Pharmaceuticals1.8435 of 5 stars$3.38-8.9%$25.00+639.6%-99.8%$3.89MN/A-0.055Upcoming EarningsShort Interest ↓Gap UpTTNPTitan Pharmaceuticals1.5805 of 5 stars$4.14-1.2%N/A-50.7%$3.78M$180,000.00-0.7910Short Interest ↓Gap UpRDHLRedHill Biopharma0.4936 of 5 stars$2.94-1.8%N/A-99.2%$3.76M$3.71M0.00210Analyst ForecastShort Interest ↑Gap DownMAAQMana Capital AcquisitionN/A$0.45+2.3%N/A-73.3%$3.66MN/A0.001High Trading VolumeNBYNovaBay Pharmaceuticals1.5393 of 5 stars$0.62-4.3%$0.85+37.1%-84.0%$3.61M$13.84M-0.0130PPBTPurple Biotech2.0695 of 5 stars$2.69-1.5%$33.00+1,126.8%N/A$3.58MN/A-0.3120ATNF180 Life SciencesN/A$1.11-1.8%N/A-56.0%$3.53MN/A0.007Short Interest ↑SNPXSynaptogenix2.1568 of 5 stars$2.57-0.8%$14.00+444.7%-48.4%$3.49MN/A0.004Earnings ReportUpcoming EarningsINMInMed Pharmaceuticals1.4444 of 5 stars$2.85+2.5%N/A-71.6%$3.44M$4.83M-0.2110Short Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies IM Cannabis Alternatives CNS Pharmaceuticals Alternatives Titan Pharmaceuticals Alternatives RedHill Biopharma Alternatives Mana Capital Acquisition Alternatives NovaBay Pharmaceuticals Alternatives Purple Biotech Alternatives 180 Life Sciences Alternatives Synaptogenix Alternatives InMed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVFM Stock Free EVFM Stock Alerts